Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant min mouse adenomas, and selective toxicity against Apc mutant embryos

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1864-1870

  Jacoby, Russell F ^a,c   Cole, Carolyn E ^a   Tutsch, Kendra ^a   Newton, Michael A ^a   Kelloff, Gary ^b   Hawk, Ernest T ^b   Lubet, Ronald A ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EFLORNITHINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE DECARBOXYLASE; ORNITHINE DECARBOXYLASE INHIBITOR; PIROXICAM; PUTRESCINE; SPERMIDINE; SPERMINE; THROMBOXANE B2;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; COLON ADENOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENOTYPE; MALE; MOUSE; MULTIPLE CANCER; NONHUMAN; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SMALL INTESTINE TUMOR; TUMOR VOLUME;

ADENOMA; ANIMALS; ANTICARCINOGENIC AGENTS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; EFLORNITHINE; EMBRYO; FEMALE; GENES, APC; INTESTINAL NEOPLASMS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; ORNITHINE DECARBOXYLASE; PIROXICAM; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0034105197     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rao, C. V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G., and Reddy, B. S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16 α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res., 51: 4528-4534, 1991.
2. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
3. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc-δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
4. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., and Abreu-Goris, M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
5. Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F., Hamilton, S. R., Vogelstein, B., and Kinzler, K. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis (Lond.), 17: 1757-1760, 1996.
6. Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsch, K., Cole, C. E., Lubet, R. A., Kelloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. Chemoprevention of spontaneous intestinal adenomas in the Min/Apc mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710-714, 1996.
7. Thun, M. J., Namboodiri, M. M., and Heath, C. W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
8. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
9. Thun, M. J. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol. Clin. N. Am., 25: 333-348, 1996.
10. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. A. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
11. Piazza, G. A., Kulchak Rahm, A. L., Krulzsch, M., Sperl, G., Shipp Paranka, N., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., Pamukeu, R., and Ahnen, D. J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
12. Chan, T. A., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA, 95: 681-686, 1998.
13. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
14. Megosh, L., Gilmour, S. K., Rosson, D., Soler, A. P., Blessing, M., Sawicki, J. A., and O'Brien, T. G. Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res., 55: 4205-4209, 1995.
15. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., Beauchamp, R. D., and DuBois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111: 1134-1140, 1996.
16. DuBois, R. N., and Smalley, W. E. Cyclooxygenase, NSAIDs, and colorectal cancer. J. Gastroenterol., 31: 898-906, 1996.
17. McCann, P., Pegg. A., and Sjoerdsma, A. Inhibition of polyamine metabolism. In: Biologic significance and basis for new therapies, pp 1-371. Orlando, FL: Academic Press, 1987.
18. Verma, A. K. The enzyme-activated irreversible inhibitor of ornithine decarboxylase, D,L-α-difluoromethylornithine: a chemopreventive agent. Prev. Med., 18: 646-652, 1989.
19. Giardiello, F. M., Hamilton, S. R., Hylind, L. M., Yang, V. W., Tamez, P., and Casero, R. A. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res., 57: 199-201, 1997.
20. Reddy, B. S., Naylor, S., Tokumo, K., Rigotty, J., Zang, E., and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res., 50: 2562-2568, 1991.
21. Meyskens, F. L., Emerson, S. S., Pelot, D., Meshkinpopur, H., Shassetz, L. R., Einspahr, J., Alberts, D. S., and Gerner, E. W. Dose de-escalation chemoprevention trial of difluoromethylornithine in patients with colon polyps. J. Natl. Cancer Inst., 86: 1122-1130, 1994.
22. Love, R. R., Jacoby, R. F., Newton, M. A., Tutsch, K. D., Simon, K., Pomplun, M., and Verma, A. K. A randomized, placebo-controlled trial of low-dose α-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol. Biomark. Prev., 7: 989-992, 1998.
23. Everhart, J. E. Digestive Diseases in the United States: Epidemiology and Impact, NIH Publication 94-1447, pp. 357-408. Bethesda, MD: NIH, 1994.
24. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., Miyashiro, J. M., Penning, T. D., Seibert, K., Isakson, P. C. and Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (Lond.), 384: 644-648, 1996.
25. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc-δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
26. Masferrer, J., Zweifel, B., and Manning, P. T. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA, 91: 3228-3232, 1994.
27. Anzano, M. A., Byers, S. W., Smith, J. M., Peer, C. W., Mullen, L. T., Brown, C. C., Roberts, A. B., and Sporn, M. B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res., 54: 4614-4617, 1994.
28. Jacoby, R. F., Cole, C. E., Seibert, K., Kelloff, G. J., and Lubet, R. A. The specific cyclooxygenase-2 inhibitor, celecoxib, causes adenoma regression in the Apc mutant Min mouse. Gastroenterology, 116: A428, 1999.
29. Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Could, K. A., and Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (Washington DC), 256: 668-670, 1992.
30. Smithers, J. A precolumn derivitization high-performance liquid chromatographic (HPLC) procedure for the quantification of difluoromethylornithine in plasma. Pharm. Res. (N.Y.), 5: 684-686, 1988.
31. Macek, J., and Vacha, J. Rapid and sensitive method for determination of piroxicam in dog, rat and human plasma by high-performance liquid chromatography. J. Chromatogr., 420: 445-449, 1987.
32. Kabra, P. M., Lee, H. K., Lubich, W. P., and Marton, L. J. Solid phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: improved separation systems for polyamines in cerebral spinal fluid, urine and tissue. J. Chromatogr., 380: 19-32, 1986.
33. Newton, M. A., Larget, B., Chappell, R., and Jacoby, R. F. Random allocations in comparative experiments of known size: balance without blocking. Biostatistics and Medical Informatics, 124: 1-29, 1998.
34. Moser, A. R., Pitot, H. C., and Dove, W. F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science (Washington DC), 247: 322-324. 1990.
35. Dove, W. F., Luongo, C., Connelly, C. S., Gould, K. A., Shoemaker, A. R., Moser, A. R., and Gardner, R. L. The adenomatous polyposis coli gene of the mouse in development and neoplasia. In: Cold Spring Harbor Symp. Quant. Biol., Vol. LIX, pp. 501-508. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1994.
36. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nat. New Biol., 231: 232-235, 1971.
37. Tempero, M. A., Nishioka, K., Knott, K., and Zetterman, R. K. Chemoprevention of mouse colon tumors with difluoromethylorinithine during and after carcinogen treatment. Cancer Res., 49: 5793-5797, 1989.
38. Arbeit, J. M., Riley, R., Huey, B., Porter, C., Kelloff, G., Lubet, R., Ward, J. M., and Pinkel, D. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res., 59: 3610-3620, 1999.